CPI-613 (devimistat) + FOLFIRINOX
Metastatic Pancreatic Adenocarcinoma
Key Facts
Indication
Metastatic Pancreatic Adenocarcinoma
Phase
Phase 3
Status
Active, not recruiting
Company
About Rafael Holdings
Rafael Holdings is a clinical-stage oncology company leveraging its expertise in cancer metabolism to develop innovative therapeutics. Its core asset, CPI-613, is a lipoate analog that disrupts key mitochondrial enzymes, inducing selective cancer cell death. The company is advancing CPI-613 through multiple clinical trials, primarily in combination regimens, and maintains a strategic focus on aggressive and rare cancers with high unmet need.
View full company profileTherapeutic Areas
Other Metastatic Pancreatic Adenocarcinoma Drugs
| Drug | Company | Phase |
|---|---|---|
| motixafortide (BL-8040) | BioLineRx | Phase 2b |